Spero Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Spero Therapeutics, Inc. (SPRO) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $7.20 per share as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-08-12
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $7.20.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $7.52.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $9.98.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $9.98.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $7.20 10-Q · filed 2026-08-12 |
| 2026-03-31 | $7.52 10-Q · filed 2026-05-13 |
| 2025-12-31 | $9.98 10-K · filed 2026-03-26 |
| 2025-09-30 | $9.98 10-Q · filed 2025-11-13 |
| 2025-06-30 | $10.35 10-Q · filed 2025-08-12 |
| 2025-03-31 | $10.47 10-Q · filed 2025-05-13 |
| 2024-12-31 | $10.71 10-K · filed 2025-03-27 |
| 2024-09-30 | $10.73 10-Q · filed 2024-11-14 |
| 2024-06-30 | $10.74 10-Q · filed 2024-08-05 |
| 2024-03-31 | $10.75 10-Q · filed 2024-05-15 |
| 2023-12-31 | $10.89 10-K · filed 2024-03-13 |
| 2023-09-30 | $10.95 10-Q · filed 2023-11-13 |
| 2023-06-30 | $10.76 10-Q · filed 2023-08-10 |
| 2023-03-31 | $10.87 10-Q · filed 2023-05-11 |
| 2022-12-31 | $10.99 10-K · filed 2023-03-30 |
| 2022-09-30 | $11.00 10-Q · filed 2022-11-14 |
| 2022-06-30 | $11.06 10-Q · filed 2022-08-10 |
| 2022-03-31 | $11.63 10-Q · filed 2022-05-16 |
| 2021-12-31 | $11.75 10-K · filed 2022-03-31 |
| 2021-09-30 | $11.56 10-Q · filed 2021-11-10 |
| 2021-06-30 | $11.22 10-Q · filed 2021-08-05 |
| 2021-03-31 | $11.18 10-Q · filed 2021-05-06 |
| 2020-12-31 | $9.10 10-K · filed 2021-03-11 |
| 2020-09-30 | $8.59 10-Q · filed 2020-11-05 |
| 2020-06-30 | $8.54 10-Q · filed 2020-08-06 |
| 2020-03-31 | $8.42 10-Q · filed 2020-05-08 |
| 2019-12-31 | $8.13 10-K · filed 2020-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |